Nabilone & Marijuana Addiction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01025700 |
Recruitment Status :
Completed
First Posted : December 3, 2009
Last Update Posted : February 17, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Marijuana Smoking | Drug: Cesemat | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 35 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal |
Study Start Date : | June 2009 |
Actual Primary Completion Date : | June 2010 |
Actual Study Completion Date : | October 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Cesemat |
Drug: Cesemat
1 mg capsule per day for 21 days
Other Name: Nabilone |
No Intervention: Placebo |
- Safety and tolerability to Nabilone
- Marijuana craving questionnaire

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 19 years or older
- History of marijuana use

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01025700
Canada, British Columbia | |
Vancouver General Hospital - Psychiatry Outpatient | |
Vancouver, British Columbia, Canada |
Principal Investigator: | Shaohua Lu, MD | University of British Columbia |
Responsible Party: | Shaohua Lu, MD, University of British Columbia |
ClinicalTrials.gov Identifier: | NCT01025700 |
Other Study ID Numbers: |
H08-01999 |
First Posted: | December 3, 2009 Key Record Dates |
Last Update Posted: | February 17, 2011 |
Last Verified: | February 2011 |
Efficacy Marijuana Reduction Craving |
Marijuana Abuse Marijuana Use Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Nabilone Antiemetics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs |